Clinical Trial Update: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a combination of a CD40 agonist, FLT3 ligand, and chemotherapy in HER2-negative breast cancer. The study includes patients wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CD40 agonist
• Chemotherapy (chemotherapy)
• FLT3 ligand (FLT3 ligand)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 1 | Status: RECRUITING